Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery

Journal of Extra-Corporeal Technology

Volumn 42, Issue 1, 2010, Pages 9-19

  Gruenwald, Colleen E ^a,b   Manlhiot, Cedric ^a   Crawford Lean, Lynn ^a   Foreman, Celeste ^a   Brandão, Leonardo R ^a   McCrindle, Brian W ^a   Holtby, Helen ^a   Richards, Ross ^b   Moriarty, Helen ^b   Van Arsdell, Glen ^a   Chan, Anthony K ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b CHARLES STURT UNIVERSITY   (Australia)

^c MCMASTER CHILDREN S HOSPITAL   (Canada)

Author keywords

Anticoagulation; Cardiopulmonary bypass; Homeostasis; Pediatrics

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; HEPARIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROTAMINE; PROTEIN C; PROTEIN S; THROMBIN; TUMOR NECROSIS FACTOR;

ACCURACY; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CYANOSIS; EVIDENCE BASED MEDICINE; HEART SURGERY; HEMODILUTION; HEMOSTASIS; HOMEOSTASIS; HUMAN; INFLAMMATION; LOADING DRUG DOSE; LUNG EMBOLISM; NONHUMAN; PATIENT MONITORING; REVIEW; RISK; THROMBOCYTE ACTIVATION; THROMBOCYTE DYSFUNCTION; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 77950802426     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Review

References (129)

1. Monagle P. Thrombosis in children with BT shunts, Glenns and Fontans. Prog Pediatr Cardiol. 2005;21:17-21.
2. Cholette JM, Rubenstein JS, Alfieris GM, et al. Elevated risk of thrombosis in neonates undergoing initial palliative cardiac surgery. Ann Thorac Surg. 2007;84:1320-1325.
3. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95:362-372.
4. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80:1998-2005.
5. Svenmarker S, Appelblad M, Jansson E, Haggmark S. Measurement of the activated clotting time during cardiopulmonary bypass: Differences between HemoTec ACT and Hemochron Jr apparatus. Perfusion. 2004;19:289-294.
6. Jobes DR, Nicolson SC, Steven JM, Manno CS. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1993; 55:1283-1284.
7. Shayevitz JR, O'Kelley SW. A reappraisal of anticoagulation and heparin neutralization for cardiopulmonary bypass in pediatrics. In: Eisenkraft JB, ed. Progress in Anesthesiology. San Antonio, TX: Dannemiller Memorial Education Foundation; 1995:275-296.
8. Ichinose F, Uezono S, Muto R, et al. Platelet hyporeactivity in young infants during cardiopulmonary bypass. Anesth Analg. 1999;88: 258-262.
9. Lake CL. Pediatric Cardiac Anesthesia, 3rd Ed. Norwalk, CT: Appleton & Lange; 2005.
10. Malviya S. Monitoring and management of anticoagulation in children requiring extracorporeal circulation. Semin Thromb Hemost. 1997;23:563-567.
11. Kern FH, Morana NJ, Sears JJ, Hickey PR. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1992;54:541-546.
12. Comfurius P, Senden JM, Tilly RH, Schroit AJ, Bevers EM, Zwaal RF. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta. 1990;1026:153-160.
13. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: An isolated defect in platelet procoagulant activity. J Biol Chem. 1989;264: 17049-17057.
14. Chan AK, Leaker M, Burrows FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 1997;77:270-277.
15. Mossinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg. 1998;65:S45-50; discussion S1, S74-6.
16. Saatvedt K, Lindberg H, Geiran OR, et al. Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin- 6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. Scand J Clin Lab Invest. 1995;55:79-86.
17. Owings JT, Pollock ME, Gosselin RC, Ireland K, Jahr JS, Larkin EC. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. Arch Surg. 2000;135:1042-1047.
18. Kajimoto H, Nakazawa M, Murasaki K, et al. Increased thrombogenesity in patients with cyanotic congenital heart disease. Circ J. 2007;71:948-953.
19. Hezard N, Potron G, Schlegel N, Amory C, Leroux B, Nguyen P. Unexpected persistence of platelet hyporeactivity beyond the neonatal period: A flow cytometric study in neonates, infants and older children. Thromb Haemost. 2003;90:116-123.
20. Harker LA, Malpass TW, Branson HE, Hessel EA II, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980;56:824-834.
21. Rinder CS, Gaal D, Student LA, Smith BR. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1994;107:280-288.
22. Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology. 1994;80:520-526.
23. Edmunds LH. Cardiopulmonary bypass after 50 years. N Engl J Med. 2004;351:1603-1606.
24. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:S715-20.
25. Chew MS, Brandslund I, Brix-Christensen V, et al. Tissue injury and the inflammatory response to pediatric cardiac surgery with cardiopulmonary bypass: A descriptive study. Anesthesiology 2001;94:745- 53; discussion 5A.
26. Ashraf SS, Tian Y, Zacharrias S, Cowan D, Martin P, Watterson K. Effects of cardiopulmonary bypass on neonatal and paediatric inflammatory profiles. Eur J Cardiothorac Surg. 1997;12:862-868.
27. Seghaye MC, Grabitz RG, Duchateau J, et al. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac Cardiovasc Surg. 1996;112:687-697.
28. Petaja J, Lundstrom U, Sairanen H, Marttinen E, Griffin JH. Central venous thrombosis after cardiac operations in children. J Thorac Cardiovasc Surg. 1996;112:883-889.
29. Jensen E, Andreasson S, Bengtsson A, et al. Changes in hemostasis during pediatric heart surgery: Impact of a biocompatible heparincoated perfusion system. Ann Thorac Surg. 2004;77:962-967.
30. Spiess BD. The contribution of fibrinolysis to postbypass bleeding. J Cardiothorac Vasc Anesth. 1991;5:13-17.
31. Williams GD, Bratton SL, Riley EC, Ramamoorthy C. Association between age and blood loss in children undergoing open heart operations. Ann Thorac Surg. 1998;66:870-5, discussion 5-6.
32. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood. 1987;70:165-172.
33. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol. 1990;12:95-104.
34. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood. 1988;72: 1651-1657.
35. Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood. 1991;78:2299-2304.
36. Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest. 1990;86:107-112.
37. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost. 1994;72:836-842.
38. Hakacova N, Laluhova-Striezencova Z, Zahorec M. Disturbances of coagulation in neonates with functionally univentricular physiology prior to the first stage of surgical reconstruction. Cardiol Young. 2008;18:397-401.
39. McEwan A. Aspects of bleeding after cardiac surgery in children. Paediatr Anaesth. 2007;17:1126-1133.
40. Chambers LA, Cohen DM, Davis JT. Transfusion patterns in pediatric open heart surgery. Transfusion. 1996;36:150-154.
41. Slonim AD, Joseph JG, Turenne WM, Sharangpani A, Luban NL. Blood transfusions in children: A multi-institutional analysis of practices and complications. Transfusion. 2008;48:73-80.
42. Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: A multivariate analysis in children after open-heart surgery. Anesth Analg. 1999;89:57-64.
43. Manno CS, Hedberg KW, Kim HC, et al. Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood. 1991;77:930-936.
44. Gruenwald C, McCrindle BW, Crawford LE, et al. Reconstituted fresh whole blood improves clinical outcomes compared to stored component blood therapy for neonates undergoing cardiopulmonary bypass for cardiac surgery: A randomized controlled trial. Journal of Cardiothoracic and Vascular Surgery. 2008;136:1442-1449.
45. Cauwenberghs S, van Pampus E, Curvers J, Akkerman JW, Heemskerk JW. Hemostatic and signaling functions of transfused platelets. Transfus Med Rev. 2007;21:287-294.
46. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229-1239.
47. Levin E, Wu J, Devine DV, et al. Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid. Thromb Haemost. 2000;83:54-59.
48. Andrew M, Monagle P, Brooker LA. Thromboembolic Complications during Infancy and Childhood. Hamilton/London: B.C. Decker Inc.; 2000.
49. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood. 1994;83:1251-1257.
50. Schmidt B, Andrew M. Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics. 1995;96:939-943.
51. van Ommen CH, Heijboer H, Buller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: A prospective two-year registry in The Netherlands. J Pediatr. 2001;139:676-681.
52. Chan AK, Deveber G, Monagle P, Brooker LA, Massicotte PM. Venous thrombosis in children. J Thromb Haemost. 2003;1:1443-1455.
53. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124:1001-1008.
54. Alioglu B, Avci Z, Tokel K, Atac FB, Ozbek N. Thrombosis in children with cardiac pathology: Analysis of acquired and inherited risk factors. Blood Coagul Fibrinolysis. 2008;19:294-304.
55. Ozbek N, Alioglu B, Avci Z, et al. Incidence of and risk factors for childhood thrombosis: A single-center experience in Ankara, Turkey. Pediatr Hematol Oncol. 2009;26:11-29.
56. Hausler M, Hubner D, Delhaas T, Muhler EG. Long term complications of inferior vena cava thrombosis. Arch Dis Child. 2001;85: 228-233. (Pubitemid 32822384)
57. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107:I22-30.
58. Kuhle S, Koloshuk B, Marzinotto V, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res. 2003; 111:227-233. (Pubitemid 38021940)
59. Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: A comprehensive review of the literature. Thromb Haemost. 1996;76:132-134. (Pubitemid 26285237)
60. Revel-Vilk S, Sharathkumar A, Massicotte P, et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: A longitudinal study by ultrasound. J Thromb Haemost. 2004;2:42-46. (Pubitemid 40185617)
61. Kaulitz R, Ziemer G, Rauch R, et al. Prophylaxis of thromboembolic complications after the Fontan operation (total cavopulmonary anastomosis). J Thorac Cardiovasc Surg. 2005;129:569-575. (Pubitemid 40311316)
62. Male C, Kuhle S, Mitchell L. Diagnosis of venous thromboembolism in children. Semin Thromb Hemost. 2003;29:377-390.
63. Prandoni P, Bernardi E. Upper extremity deep vein thrombosis. Curr Opin Pulm Med. 1999;5:222-226.
64. Kenet G, Kirkham F, Niederstadt T, et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: A multicentre cohort study. Lancet Neurol. 2007;6:595-603.
65. Monagle P. Thrombosis in pediatric cardiac patients. Semin Thromb Hemost. 2003;29:547-555.
66. Biss TT, Brandao LR, Kahr WH, Chan AK, Williams S. Clinical features and outcome of pulmonary embolism in children. Br J Haematol. 2008;142:808-818.
67. deVeber G, Andrew M, Adams C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med. 2001;345:417-423.
68. deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol. 2000;15:316-324.
69. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med. 2004;351:1081-1088. (Pubitemid 39167512)
70. Vu LT, Nobuhara KK, Lee H, Farmer DL. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg. 2008;43:1095-1099. (Pubitemid 351814911)
71. Henke P, Froehlich J, Upchurch G Jr, Wakefield T. The significant negative impact of in-hospital venous thromboembolism after cardiovascular procedures. Ann Vasc Surg. 2007;21:545-550. (Pubitemid 47333057)
72. Brown KL, Ridout DA, Goldman AP, Hoskote A, Penny DJ. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med. 2003;31:28-33. (Pubitemid 36151145)
73. Gillespie M, Kuijpers M, Van Rossem M, et al. Determinants of intensive care unit length of stay for infants undergoing cardiac surgery. Congenit Heart Dis. 2006;1:152-160. (Pubitemid 44102900)
74. Anton N, Massicotte MP. Venous thromboembolism in pediatrics. Semin Vasc Med. 2001;1:111-122.
75. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47:763-766.
76. van Ommen CH, Ottenkamp J, Lam J, et al. The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr. 2002;141:582-586. (Pubitemid 35193328)
77. Marzinotto V, Choi M, Chan AK, Andrew M. Post-thrombotic syndrome in children with previous deep venous thrombosis. XVIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), 2001, Paris, France.
78. Heying R, van Oeveren W, Wilhelm S, et al. Children undergoing cardiac surgery for complex cardiac defects show imbalance between pro- and anti-thrombotic activity. Crit Care. 2006;10:R165.
79. Alsoufi B, Al-Radi OO, Gruenwald C, et al. Extra-corporeal life support following cardiac surgery in children: Analysis of risk factors and survival in a single institution. Eur J Cardiothorac Surg. 2009;35:1004-1011, discussion 11.
80. Best CH. Preparation of heparin and its use in the first clinical cases. Circulation. 1959;19:79-86.
81. Hudson WA. The physiological aspects of extracorporeal circulation. Br J Anaesth. 1959;31:378-392.
82. Mclean J. The discovery of heparin. Circulation. 1959;19:75-78.
83. Rothnie NG, Kinmonth JB. Bleeding after perfusion for open heart surgery. Importance of unneutralized heparin and its proper correction. BMJ. 1960;1:73-78.
84. Edmunds LH Jr, Colman RW. Thrombin during cardiopulmonary bypass. Ann Thorac Surg. 2006;82:2315-2322.
85. Bahnson HT, Spencer FC, Landtman B, Wolf MD, Neill CA, Taussig HB. Surgical treatment and follow-up of 147 cases of tetralogy of Fallottreated by correction. J Thorac Cardiovasc Surg. 1962;44:419-432.
86. Castaneda AR. Must heparin be neutralized following open-heart operations? J Thorac Cardiovasc Surg. 1966;52:716-724.
87. Roberts KD. Cardiopulmonary bypass in neonates. BMJ. 1962;1: 1183-1185.
88. Berger RL, Ramaswamy K, Ryan TJ. Reduced protamine dosage for heparin neutralization in open-heart operations. Circulation. 1968;37:II154-7.
89. Doty DB, Knott HW, Hoyt JL, Koepke JA. Heparin dose for accurate anticoagulation in cardiac surgery. J Cardiovasc Surg (Torino). 1979;20:597-604. (Pubitemid 10177438)
90. Babka R, Colby C, El-Etr A, Pifarre R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg. 1977;73:780-782. (Pubitemid 8088441)
91. Hattersley PG. Activated coagulation time of whole blood. JAMA. 1966;196:436-440.
92. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69:674-684.
93. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685-689.
94. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg. 1978;26:231-240.
95. Jumean HG, Sudah F. Monitoring of anticoagulant therapy during open-heart surgery in children with congenital heart disease. Acta Haematol. 1983;70:392-395. (Pubitemid 14248250)
96. Litwin SB, Mitra SK, Von Colditz R, et al. Use of activated clotting time for monitoring anticoagulation during cardiopulmonary bypass in infants and children with congenital heart disease. Cardiovasc Dis. 1981;8:364-371. (Pubitemid 11020925)
97. Despotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1994; 107:271-279. (Pubitemid 24050528)
98. Jobes DR, Schwartz AJ, Ellison N, Andrews R, Ruffini RA, Ruffini JJ. Monitoring heparin anticoagulation and its neutralization. Ann Thorac Surg. 1981;31:161-166. (Pubitemid 11173189)
99. Harle CC, Murkin JM. Another bleeding heart: Perioperative heparin management revisited. Can J Anaesth. 2007;54:97-102.
100. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol. 1995;75:559-562.
101. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg. 1984;63:394-398.
102. Gravlee GP, Arora S, Lavender SW, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg. 1994;58:216-221. (Pubitemid 24243933)
103. Andrew M, MacIntyre B, MacMillan J, et al. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemost. 1993;70:937-941. (Pubitemid 24008803)
104. Ferguson JJ. All ACTs are not created equal. Tex Heart Inst J. 1992;19:1-3.
105. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn. 1989;18:206-209.
106. Schriever HG, Epstein SE, Mintz MD. Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood coagulation time, and an automated coagulation time. Am J Clin Pathol. 1973;60:323-329.
107. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg. 1981;193:105-111. (Pubitemid 11130881)
108. Guzzetta NA, Bajaj T, Fazlollah T, et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg. 2008;106:419-425. (Pubitemid 351156664)
109. Sade RM, Bartles DM, Dearing JP, Campbell LJ, Loadholt CB. A prospective randomized study of membrane versus bubble oxygenators in children. Ann Thorac Surg. 1980;29:502-511. (Pubitemid 10063437)
110. D'Errico C, Shayevitz JR, Martindale SJ. Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients. J Cardiothorac Vasc Anesth. 1996;10:451-457. (Pubitemid 26177752)
111. Jaberi M, Bell WR, Benson DW. Control of heparin therapy in openheart surgery. J Thorac Cardiovasc Surg. 1974;67:133-141.
112. Turner-Gomes SO, Nitschmann EP, Norman GR, Andrew ME, Williams WG. Effect of heparin loading during congenital heart operation on thrombin generation and blood loss. Ann Thorac Surg. 1997;63:482-488.
113. Despotis GJ, Filos KS, Levine V, Alsoufiev A, Spitznagel E. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg. 1996; 82:1126-1131. (Pubitemid 26157990)
114. Altshuler JH, Altshuler TL, Halseth WL, Elliott DP, Roos EB, Feiler E. Hemotensiometry. A new technique for the study of hemostasis in open-heart surgery. Ann Thorac Surg. 1974;18:516-530.
115. Congdon JE, Kardinal CG, Wallin JD. Monitoring heparin therapy in hemodialysis. A report on the activated whole blood coagulation time tests. JAMA. 1973;226:1529-1533.
116. Friesen RH, Clement AJ. Individual responses to heparinization for extracorporeal circulation. J Thorac Cardiovasc Surg. 1976;72: 875-879.
117. Olshove VF, Langwell J, Burnside J, Bennett D. Heparin dose response in pediatric cardiopulmonary bypass. J Extra Corpor Technol. 1994;26:126-128. (Pubitemid 24307714)
118. Despotis GJ, Joist JH, Hogue CW Jr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46-54.
119. Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: Impact of heparin management. Anesthesiology. 2002;97:837-841.
120. McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. Pediatr Res. 1981;15:1015-1018.
121. Codispoti M, Ludlam CA, Simpson D, Mankad PS. Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg. 2001;71:922-7, discussion 7-8.
122. Codispoti M, Mankad PS. Management of anticoagulation and its reversal during paediatric cardiopulmonary bypass: A review of current UK practice. Perfusion. 2000;15:191-201. (Pubitemid 30333163)
123. Taneja R, Fernandes P, Marwaha G, Cheng D, Bainbridge D. Perioperative coagulation management and blood conservation in cardiac surgery: A Canadian Survey. J Cardiothorac Vasc Anesth. 2008;22:662-669.
124. Martindale SJ, Shayevitz JR, D'Errico C. The activated coagulation time: Suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 1996;10:458-463. (Pubitemid 26177753)
125. Guzzetta NA, Miller BE, Todd K, Szlam F, Moore RH, Tosone SR. An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg. 2005;100:1276-1282. (Pubitemid 40577369)
126. Horkay F, Martin P, Rajah SM, Walker DR. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg. 1992;53:822-826.
127. Okita Y, Takamoto S, Ando M, et al. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: The importance of adequate heparinization. Circulation. 1997;96:II-376-381. (Pubitemid 27500060)
128. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391. (Pubitemid 20271869)
129. Despotis GJ, Gravlee G, Filos K, Levy J. Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques. Anesthesiology. 1999;91:1122-1151. (Pubitemid 29466546)